Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OSP:rTTHc Cholera Conjugate Vaccine in Healthy Adults
NCT05559983Phase 1Completed
- Sponsor
- International Vaccine Institute
- Start
- Dec 2022
- Primary completion
- Sep 2023
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Cholera conjugate vaccine in cholera (3 arms), sponsored by International Vaccine Institute. Primary endpoints: Serious adverse events (SAEs) and adverse events of special interest (AESIs) at 7 months, Immediate adverse events at 30 minutes and 3 more. Started Dec 2022; status: completed.
02
Drugs
Cholera conjugate vaccine
03
Conditions
cholera
Beyond the preview
Go deeper on NCT05559983.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05559983.